Other languages Azitra, Inc.

Equities

AZTR

US05479L1044

Market Closed - Nyse Other stock markets 01:30:00 25/05/2024 am IST			5-day change	1st Jan Change
0.1902 ^USD	-5.89%		-2.36%	-79.33%

10/05	Azitra, Inc. Announces Positive Preclinical Data of ATR-12 and Clinical Design in Netherton Syndrome Presented at the ASGCT Annual Meeting	CI
09/05	Azitra, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Azitra, Inc. Announces Positive Preclinical Data of ATR-12 and Clinical Design in Netherton Syndrome Presented at the ASGCT Annual Meeting	10/05
Azitra, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	10/05
Azitra, Inc. Announces New Preclinical Data to be Presented at the American Society of Gene and Cell Therapy Meeting	23/04
Azitra, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	16/03
Azitra Closes $5 Million Public Offering	17/02
Top Midday Decliners	15/02
Azitra Prices Stock Offering at $0.30 a Share	14/02
Azitra Launches Common Stock Offering; Shares Drop	19/01
Azitra, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2023	15/11
Azitra Adds Barbara Ryan and John Schroer to Its Board of Directors	20/23/20
Azitra, Inc. Appoints Travis Whitfill as Chief Operating Officer	11/23/11
Top Premarket Decliners	06/23/06
Insider Buy: Azitra	26/23/26
Insider Buy: Azitra	26/23/26
Azitra Closes IPO, Raises $7.5 Million Gross Proceeds	22/23/22
Azitra Shares Fall in NYSE American Debut	16/23/16
Azitra, Inc. has completed an IPO in the amount of $7.5 million.	15/23/15
Azitra Inc Reports Earnings Results for the First Quarter Ended March 31, 2023	10/23/10
Azitra, Inc. has filed an IPO in the amount of $17.25 million.	21/23/21

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

+39.41% on our US portfolio vs. 25.67% on the S&P 500 net Total Return

Replicate our performance

fermer